Introduction
Although the acquired inununodeficiency syndrome (AIDS) was first reported in 1981, retrospective evaluation suggests that AIDS may have occurred in the United States almost 10 yeärs earlier. In 1984, the causative agent was identified äs a member of the human inununodeficiency virus family, HJV-1. More thän 46 000 individuals in the United States had developed AIDS by the end of 1987 (1) , and concern for the widespread transmission of the disease persists. The clinical spectrum of infectiön is broad and includes an acute viral syndrome, asymptomatic carrier state, AIDS-related cpmplex (ARG) and fulminant AIDS complicated by either Kaposi sarcoma, tymphoreticular malignancies, neurologic disorders, or opportunistic infections.
In 1985 the U.S. Food and Drag Administration (FDA) approved the first commercial reagents for measurement of antibodies to HIV-1 in human sera. Since that time* all human blood donor units have been tested and rejected for use if HIV-1 immunoenzymometric assay (IEMA) antibody results are positive. Specimens which are repetitively IEMA reactive are subjected to Western blot analyses for confirmation. Also since 1985, manufacturers of quality control sera have begün testing source plasma and rejecting HIV-1 antibody reactive sera for quality assurance pools. However, human products for transfusion and injection, and quality assurance reagents produced before HIV-1 antibody testing still may be used for a number of years before expiration. In the United States, manufacturers routinely extend product shelf life on a yearly basis far beyond their original expiration dates.
Recent reports have indicated occupational risk of AIDS to health care workers and have prompted strengthened safety programmes (2) . Whereas recipients of blood products have been at risk from treatment with infectious materials, laboratory workers may have been potentially exposed to HIV-1 infected patients, to their sera, other body fluids, or tissues. Evidence of HIV-1 infectiön requires identification of specific serum IgG antibodies or Isolation of virus from circulating peripheral blood lymphocytes, monocytes, or macrophages. Recent reports have indicated a high incidence of HIV-1 antibodies in human serum-based quality assurance reagents and immune globulin preparations (3-7), although no reports of individuals infected from these products have appeared. In contrast, whole blood packed red cells, factor VIII, and cryo-preserved serum are among the products reported to frequently cause AIDS when transferred to non-infected humans. Procedures based on identification of HIV-1 antibodies have been subject to interferences including non-specific antibodies to the H-9 cell line from which viral antigens used in various assays were obtained (8) , heating n n-reactive sera (9) (10) (11) , and passive transfer of HIV-1 antibodies following treatment with human immune globulins (12) . Viral Isolation is time-consuming, expensive, and cannot be used for large numbers of specimens. Recently circulating HIV-1 antigen was detected in sera of infected individuals who developed specific HIV-1 antibodies (13) , This antigen has also been found later during the course of infection in homosexuals, haemophiliacs, children born to sera positive mothers, and in high frequency in sera of individuals with AIDS. The purpose of the present study was to investigate the prevalence of HIV-1 antigens in quality assurance sera and immune serum globulin preparations classified s HIV-1 antibody reactive and non-reactive. We also wanted to determine whether HIV-1 antigen testing might be used alone or with HIV-1 antibody testing to increase the likelihood of identifying HIV-1 reactive sera.
Materials and Methods
Previously we tested and classified HIV-1 antibody reactivity of quality assurance samples and human immune globulin preparations using the HTLV-III (HIV-l) IEMA test kit produced by Abbott Laboratories, North Chicago IL, 60064, U. S. A. (3, 5) . We substantiated antibody reactivity of some samples by a second IEMA and Western blot analysis and subsequently tested 15 additional quality assurance samples by the same Abbott technique.
We then tested all human immune serum preparations and quality assurance samples with the Abbott HIV-1 Ag IEMA test kit which uses polystyrene beads coated with human antibody to HIV-1. A 200 μΐ sample or control was pipetted into wells of a reaction tray and then incubated with antibody coated beads. After incubation for 16-20 h at room temperature, excess sample was aspirated and the beads were washed. Next, 200 μΐ of rabbit antibody to HIV-1 was added and incubated at 4 °C for 4 h. Excess material was aspirated and beads were washed s before. Following addition of 200 μΐ of goat antirabbit IgG conjugated to horseradish peroxidase and incubation at 4 °C for 2 h, the unbound material again was aspirated and the beads were washed. On addition of 300 μΐ of an orthophenylenediamine solution with hydrogen peroxide, the beads were incubated for 30 min at room temperature, and l ml of 0.5 mol/1 sulphuric acid was added and the colour intensity read at 492 nm using a Quantum II analyser (Abbott Laboratories 
Results
Table l lists 18 human-serum-based non-proficiency samples, 36 human serum-Jbased proficiency samples and 1l bovine-serum^based non-proficiency samples which were non-reactive for HIV antibody s measured by the Abbott IEMA. Samples produced by Beckman and Clinical Chemistry Consultants were in a liquid matrix whereas all others were human lyophilized products. All 64 samples were non-reactive for HIV-1 antigens.
Listed in table 2 are 24 n n-proficiency samples and 20 proficiency samples which were HIV-1 antibody positive. The products listed are human-serum-based except those produced by Beckman. Fourteen had· been tested for Western blot reactivity and eight found reactive for at least p24. The 44 specimens were found non-reactive for HIV-1 antigens. Shown in table 3 are 14 human immune serum globulin preparations reactive for HIV-1 antibody by the AbbotMEMA. Three were Western blot positive (p24 and gp41), and eleven indeterminate (at least p24, p31 and p55), except for the Varicella-Zoster preparation (p55). The 14 human immune serum globulin preparations were negative for HIV-1 .antigens. 
Discussion
Shortly after infectiön with HIV-1, viral antigens appear transiently in human sera followed by antibodies to viral envelope structural glycoprotein (gp41) and then the core structural proteins p!5, p!8, p24 and p55 (13) . The Abbott HIV-1 Ag assay uses human polyclonal antibody reagent to viral core antigen p24 and envelope antigen gp41. Assay analytical sensitivity is approximately 30 to 40 ng/1 for p24 and 200 to 300 ng/1 for gp41. Average HIV-1 Ag values in AIDS patients are approximately 100 to 500 ng/1 with levels äs high äs 30 g/l in some patients (14) .
Our previoüs studies indicate that the prevalence of HIV-1 antibodies in quality assurance sera or huinan immune globulin reagents was 31 and 100%, respectively (3, 5) , and approximates to the seropositivity in high risk groups. This book is a comprehensive and up-to-date review on the importance of selenium in human and animal nutrition. Starting from physiological aspects, it covers epidemiological and clinical data, giving detailed information on selenium requirements, supplementation and toxicity, and the methods for assessing selenium Status. It includes contributions from famous experts and specialists in the field. Although 44 quality assurance samples and 15 intravenous globulin preparations were reactive for HIV-1 antibodies, none was reactive for HIV-1 antigen.
Three of the quality assurance samples and 14 human immune globulin reagents previously had been tested and found to be Western blot positive (presence of p24 and gp41). Recently, widely accepted criteria for Western blot positivity have been developed, and they include reactivity for any two of the following viral proteins: p24, gp41 and gpl20/gpl60 (16) . This lack of antigen reactivity may indicate that sera for these reagents was obtained from donors during the carrier state when HIV-1 antigen is absent and antibodies are pfesent. These findings are analogous to the report that when the HIV-1 antibody-reactive sera from 13 homosexual men supposedly in the carrier state were tested for HIV-1 antigen, only one showed antigenaemia (17) . When serum specirnens from individuals with fulminant AIDS are tested by Western blot technique they routinely have the gp41 antibody without the p24 antibody (15) . However, 21 Western blot results of biological reagents previously reported by us had p24 reactivity without gp41 reactivity. When Western blot reactivity was studied using sera from a large group of patients with AIDS or at a high risk for AIDS, approximately 40% had gp41 bands only (18) . The sera used for our studies may have been obtained from a group of patients whose disease had not progressed to "fulminant'* AIDS, but were asymptomatic carriers. It has been reported that individuals who are identified in high risk groups for AIDS voluntarily refrain from blood donation (18) . A similar voluntary deferral may also occur in those individuals who are donors of sera for quality assurance reagents. Alternatively these individuals may be too ill with fulminant AIDS to consider sera donation. Because laboratory quality assurance reagents represent sera pooled from up to 2000 donors, another potential reason for antigen non-reactivity may be reaction of an antigen reactive unit with an antibody reactive unit thereby rendering antigen non-detectable.
The inability to culture HIV-1 from quality assurance reagents and lack of substantiated infectivity of human immune globulins support our findings that antigen was not detected in products tested (20) . Recent reports have presented evidence that heating nonreactive specimens causes false positive results (9 -11), and sample treatment and handling by manufacturers of quality assurance reagents might have been responsible for similar results. In the survey by the College of American Pathologists (CAP) false positive results for HIV-1 antibody tests were noted when quality assurance specimens were tested with reagents from one manufacturer (2). Although we used the same source of reagents for HIV-1 antibody testing, it is doubtful that our antibody results represent false positive reactivity. We validated HIV-1 antibody assay results by demonstrating parallelism between positive samples tested and sera from patients with AIDS, verified some results with a second IEMA and Western blot procedures, and found appropriate controls non-reactive. Although haemophiliacs have developed AIDS after treatment with Factor VIII, the human immune globulins we tested had been subjected to Cohn fractionation, and it is possible that viral antigen present in these preparations may have been removed by this process.
Since our report that quality assurance sera contained HIV-1 antibodieSj manufacturers of these reagents have begun testing donors, and excluding those donors who demonstrate sera reactivity for HIV-1 antibody. Sera used by the South Carolina Syphilis Survey Programme has continued to react positively for HIV-1 antibody in our hands. However, correspondence with the Organizers of this Programme indicates that this sera has been Ireated for 30 min at 56 °C to inactivate live virus, and it is known thal heating sera causes false positive HIV-1 antibody results. Heating of sera does not alter HIV-1 Ag reactivity (22) .
We postulate that sera from individuals with AIDS obtained for quality assurance reagents or human immune serum globulin preparations were obtained when donors were asymptomatic, and that HIV-1 antigen may have been removed frorri human immune serum globulins preparations during Cohn fractionation. Our findings that biological reagents tested in this study do not contain HIV-1 antigen support other evidence that quality assurance reagents and human immune serum globulins do not contain viable Virus. This should not deter clinical labo/ratories from safety practices in which all samples are considered infectious.
